Clinical trials: Non-Hodgkin Lymphomas
Relapsed/Refractory Peripheral T Cell Lymphoma
A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
This is a randomized, double-blind, multi-center, phase III clinical trial designed to evaluate the efficacy of XNW5004 tablets versus Chidamide in Relapsed/Refractory PTCL, with a target of enrolling 120 subjects.
- Trial name
- NCT06776952
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Evopoint Biosciences Inc.
Large Cell Lymphoma
Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma
This multi-center, phase II study will be conducted to define the toxicity profile and antitumor activity of SGN-30 in patients with pcALCL and other closely related lymphoproliferative disorders.
- Trial name
- NCT00099255
- Testing
- SGN-30
- Where
- 13 sites in United States
- Volunteers
- 40 people
- Sponsor
- Seagen Inc.
Somatostatin Receptor Positive (SSTR+), Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
The purpose of the current study is to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive…
- Trial name
- NETTER-3 (NCT06784752)
- Testing
- [177Lu]Lu-DOTA-TATE, Octreotide LAR
- Where
- 67 sites in United States, Canada and 10 more
- Volunteers
- 240 people
- Sponsor
- Novartis Pharmaceuticals
Lymphoma, Follicular
A Study of Tazemetostat on Safety in Participants With Relapsed or Refractory Follicular Lymphoma With Enhancer of Zeste Homolog 2 (EZH2) Gene Mutation in Japan
The primary purpose of the study is to investigate the safety of tazemetostat in participants with relapsed or refractory follicular lymphoma with EZH2 gene mutation under daily clinical practice.
- Trial name
- NCT05228158
- Testing
- Tazemetostat
- Where
- 135 sites in Japan
- Volunteers
- 145 people
- Sponsor
- Eisai Co., Ltd.
Peripheral T-Cell Lymphoma (PTCL)
Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase 2b, open-label, non-randomized, single arm study to evaluate the safety, efficacy, and pharmacokinetics of HBI-8000 40 mg BIW in patients with relapsed or refractory PTCL (R/R PTCL).
- Trial name
- NCT02953652
- Testing
- HBI-8000
- Where
- 23 sites in Japan, South Korea
- Volunteers
- 55 people
- Sponsor
- HUYABIO International, LLC.
Follicular Lymphoma, Chronic Lymphocytic Leukemia
Safety, Pharmacodynamics, Pharmacokinetics, and Efficacy of GS-9901 in Adults With Relapsed or Refractory Follicular Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Small Lymphocytic Lymphoma
This study will evaluate the safety and tolerability of GS-9901 monotherapy in adults with follicular lymphoma (FL), marginal zone lymphoma (MZL), chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL).
- Conditions
- Follicular Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT02258555
- Testing
- GS-9901
- Where
- 6 sites in United States
- Volunteers
- 7 people
- Sponsor
- Gilead Sciences
Diffuse Large B-Cell Lymphoma
A Study to Assess Change in Disease State and Adverse Events in Korean Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Receiving Epcoritamab Injections
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) represents approximately 50% of all newly diagnosed patients with non-Hodgkin lymphoma.
- Trial name
- NCT07862764
- Volunteers
- 175 people
- Sponsor
- AbbVie
Lymphoma, Non-Hodgkin
A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
This study will investigate the safety, pharmacology, and activity of atezolizumab in combination with immunotherapy agents with or without an anti-CD20 agent (i.e., obinutuzumab) in patients with relapsed or refractory (R/R)…
- Trial name
- NCT03369964
- Testing
- Atezolizumab, Emactuzumab, Obinutuzumab
- Where
- 2 sites in United States
- Sponsor
- Hoffmann-La Roche
Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL)
Karyopharm Expanded Access Program for Selinexor
KEAP is an expanded access program designed to provide selinexor to eligible participants outside of a clinical trial before the drug has been given marketing approval by the country's regulatory agency or the drug is…
- Conditions
- Multiple Myeloma, Diffuse Large B-Cell Lymphoma (DLBCL), Sarcoma, Neuroglioblastoma
- Trial name
- KEAP (NCT07215832)
- Testing
- selinexor
- Sponsor
- Karyopharm Therapeutics Inc
Non-Hodgkin's Lymphoma
A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas
This study will evaluate the efficacy and safety of MabThera in combination chemotherapy, followed by maintenance treatment with MabThera.
- Trial name
- NCT01153971
- Testing
- rituximab
- Where
- 15 sites in Italy
- Volunteers
- 47 people
- Sponsor
- Hoffmann-La Roche
Obesity, Mild
Safety & Effectiveness of TENS Weight Management Compared to a Sham
This is a multicenter, randomized, blinded, parallel group, controlled study intended to evaluate the safety and effectiveness of treating overweight and Class 1 obese patients with the Elira System (TENS active treatment)…
- Trial name
- NCT05675384
- Testing
- TENS Active Treatment
- Where
- 6 sites in United States
- Volunteers
- 395 people
- Sponsor
- Elira, Inc.
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)
The purpose of this trial is to measure the safety and effectiveness of epcoritamab (EPKINLY™), either by itself or together with other therapies, when treating participants with B-cell non-Hodgkin Lymphoma (B-NHL).
- Trial name
- EPCORE™ NHL-2 (NCT04663347)
- Testing
- rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, rituximab and lenalidomide, rituximab and bendamustine
- Where
- 57 sites in United States, Australia and 11 more
- Volunteers
- 543 people
- Sponsor
- Genmab
Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma
A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma
The purpose of this study is to assess the safety of SyB L-0501 in combination with Rituximab to patients with aggressive B-cell non-Hodgkin's lymphoma, and to explore the recommended dose for the Phase II clinical trial.
- Conditions
- Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
- Trial name
- NCT00794638
- Testing
- SyB L-0501, Rituximab
- Where
- 4 sites in Japan
- Volunteers
- 9 people
- Sponsor
- SymBio Pharmaceuticals
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy…
- Conditions
- Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
- Trial name
- NCT04104776
- Testing
- Tulmimetostat, Enzalutamide
- Where
- 80 sites in United States, France and 5 more
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma
Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
Primary Objective: To determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for SAR245409 when administered in combination with rituximab or bendamustine plus rituximab Secondary Objectives: To determine…
- Conditions
- Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT01410513
- Testing
- SAR245409
- Where
- 3 sites in United States
- Volunteers
- 37 people
- Sponsor
- Sanofi
Alzheimer's Disease
Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease
Rosiglitazone (RSG) has been tested in clinical studies and is approved by the FDA as a treatment for type II diabetes mellitus, a disease that occurs when the body is unable to effectively use glucose.
- Trial name
- REFLECT-3 (NCT00348140)
- Testing
- Rosiglitazone Extended Release 2mg, Rosiglitazone Extended Release 8mg
- Where
- 194 sites in United States, Australia and 20 more
- Volunteers
- 1,468 people
- Sponsor
- GlaxoSmithKline
Lymphoma, Non-Hodgkin
Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell Lymphoma
The purpose of this study is to determine the selected dose of aflibercept when it is combined with R-CHOP treatment (Rituximab/Cyclophosphamide/Doxorubicin/Vincristine/Prednisone +/- intrathecal Methotrexate) administered every…
- Trial name
- NCT00644124
- Testing
- aflibercept
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Sanofi
Chronic Lymphocytic Leukemia, Lymphoma, Non-Hodgkin
An Extension Study for Subjects Who Are Deriving Benefit With Idelalisib (GS-1101; CAL-101) Following Completion of a Prior Idelalisib Study
This is a long-term safety extension study of idelalisib (GS-1101; CAL-101) in patients with hematologic malignancies who complete other idelalisib studies.
- Trial name
- NCT01090414
- Testing
- Idelalisib
- Where
- 18 sites in United States
- Volunteers
- 202 people
- Sponsor
- Gilead Sciences
Solid Tumor, Non-Hodgkin Lymphoma
Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma
The purpose of this study is to assess the safety and tolerability of gentulizumab, an anti-CD47 Monoclonal Antibody, in participants with solid tumors and non-Hodgkin lymphoma.
- Trial name
- NCT05221385
- Testing
- Gentulizumab
- Where
- 2 sites in China
- Volunteers
- 58 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Lymphoma, Non-Hodgkin
Multi-dose-escalation Safety and Pharmacokinetic Study of SAR3419 as Single Agent in Relapsed/Refractory B-cell Non Hodgkin's Lymphoma
The primary objective is to determine the maximum tolerated dose of SAR3419 and to characterize the dose limiting toxicity(ies).
- Trial name
- NCT00549185
- Testing
- SAR3419
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Sanofi